CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代肿瘤不可知靶点即将出现

Next-generation tumor-agnostic targets on the horizon.

静息肥大细胞的转录特征与 HR(+)HER2(-) 乳腺癌疾病结局改善相关

A transcriptional signature of resting mast cells is associated with improved disease outcome in HR(+)HER2(-) breast cancer.

NK 细胞在 HER2(-) 和 HER2(+) 人乳腺癌中占据独特的空间邻域

Natural killer cells occupy unique spatial neighborhoods in HER2(-) and HER2(+) human breast cancers.

血液系统恶性肿瘤中靶向 ROR1 的治疗进展

Therapeutic advances in the targeting of ROR1 in hematological cancers.

2024 年乳腺癌生物标志物：西班牙肿瘤内科学会和西班牙病理学会的更新共识声明

Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

美丽新世界——胃癌的新兴治疗

Brave new world-new and emerging treatments for gastric cancer.

在早期 HER2 阳性乳腺癌患者中，将辅助帕妥珠单抗加入曲妥珠单抗和化疗的六年绝对无侵袭性疾病生存获益：APHINITY（BIG 4-11）试验的亚群治疗效果模式图（STEPP）分析

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-po

N-的 STEPP 图未识别出明显从加用 P 中获益的亚群，N+的 STEPP 图未识别出需要降阶梯治疗的亚群。TILs 百分比似乎比临床复合风险评分更能预测 P 的治疗效果。

食管胃结合部癌免疫治疗策略的最新进展

Recent advances in immune-based approaches for the treatment of esophagogastric cancer.

免疫治疗，特别是免疫检查点抑制剂（ICI）类药物类别的引入，近年来改变了许多癌症的治疗范式。抗 PD-1 疗法现已成为局部和晚期疾病患者的新标准治疗。

Fcγ受体在 HER2 靶向乳腺癌治疗中的作用

Role of Fcγ receptors in HER2-targeted breast cancer therapy.